FibroGen (NASDAQ:FGEN) Director Rory B. Riggs sold 22,905 shares of the firm’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $55.75, for a total transaction of $1,276,953.75. Following the completion of the sale, the director now owns 411,295 shares in the company, valued at $22,929,696.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of FibroGen stock traded down $1.20 during trading on Monday, hitting $45.00. 607,252 shares of the company’s stock traded hands, compared to its average volume of 615,564. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. FibroGen has a twelve month low of $22.75 and a twelve month high of $63.00. The firm has a market cap of $3,819.21, a P/E ratio of -26.01 and a beta of 1.89.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.01. FibroGen had a negative net margin of 100.43% and a negative return on equity of 32.08%. The business had revenue of $42.51 million for the quarter, compared to analyst estimates of $45.37 million. equities analysts forecast that FibroGen will post -1.35 earnings per share for the current fiscal year.
Several research firms have issued reports on FGEN. ValuEngine upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Leerink Swann restated an “outperform” rating and issued a $88.00 price target (up from $80.00) on shares of FibroGen in a research report on Wednesday, February 28th. Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. Finally, Mizuho restated a “hold” rating and issued a $61.00 price target on shares of FibroGen in a research report on Thursday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $66.67.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of FibroGen by 4.0% during the 4th quarter. BlackRock Inc. now owns 6,326,075 shares of the biopharmaceutical company’s stock valued at $299,855,000 after acquiring an additional 244,617 shares in the last quarter. Farallon Capital Management LLC boosted its position in FibroGen by 50.7% in the fourth quarter. Farallon Capital Management LLC now owns 1,657,500 shares of the biopharmaceutical company’s stock valued at $78,566,000 after buying an additional 557,500 shares in the last quarter. Eagle Asset Management Inc. acquired a new position in FibroGen in the third quarter valued at about $46,158,000. First Trust Advisors LP boosted its position in FibroGen by 1,058.4% in the fourth quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock valued at $36,813,000 after buying an additional 709,598 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in FibroGen by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 723,869 shares of the biopharmaceutical company’s stock valued at $34,310,000 after buying an additional 2,312 shares in the last quarter. Institutional investors and hedge funds own 61.39% of the company’s stock.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.